Gentian Diagnostics ASA, has entered into a distribution agreement for its Cystatin C Immunoassay. The agreement is with one of the diagnostics companies and covers the United States, a key growth market for Cystatin C. Gentian's commercial strategy is to secure broad roll-out and acceptance of its products, which requires distribution through the global diagnostics companies. The distribution agreement forCystatin C further validates Gentian's ability to establish such commercial partnerships with global industry leaders and follows previously announced agreements with other global diagnostics companies.

Cystatin C supports early detection of reduced kidney function, which contributes to preventing severe kidney failure. The immunoassay can be adapted to all major clinical chemistry analysers.